Issue 3-21, 2022

Original article

https://doi.org/10.38025/2078-1962-2022-21-3-121-128

Efficacy of Follow-up Monitoring for Patients with Very High Cardiovascular Risk in the Omsk Region

View article (Download PDF file)



Download XML file

1,2 ORCIDOlga Yu. Korennova, 1 ORCIDInna V. Druk, 2 ORCIDSvetlana P. Podolnaya, 1,2 ORCIDMarina V. Savchenko, 1,2 ORCIDYulia E. Yuhina, 1 ORCIDLyudmila V. Shukil, 1 ORCIDElena A. Ryapolova

1 Omsk State Medical University, Omsk, Russian Federation
2 Omsk Region Clinical Cardiology Dispensary, Omsk, Russian Federation


ABSTRACT

Follow-up is the basis for the effectiveness of secondary cardiovascular prevention. Preferential drug provision is a necessary conditionfor the mass implementation of cardiac rehabilitation programs, as it ensures maximum adherence of patients to expensive drugtherapy and the need for regular doctor’s appointment. The Omsk Region has organized and operates a patient routing system aimedat timely initiation and continuous drug provision within the framework of the Federal Project “Fight against Cardiovascular Diseases”.Aim. To evaluate the effectiveness of the first year of cardiac rehabilitation in patients with very high cardiovascular risk who receivedpreferential drugs from the list approved by the Order of the Ministry of Health of the Russian Federation dated January 9, 2020 No. 1n.Material and methods. The study was conducted at the Omsk Region Clinical Cardiology Dispensary, a state-financed health careinstitution, from January 1 to December 31, 2020. A retrospective cohort study was conducted of outpatient records of patientssubjected to preferential provision of medicines, namely, those who were in the dispensary for acute stroke, myocardial infarction, orfor coronary artery bypass grafting, coronary artery stenting or catheter ablation. A clinical-expert analysis of 1502 final clinical reportsof patients who completed follow-up after one year was carried out. The patients’ adherence to dispensary observation, achievementof the target values of the main risk factors, total one-year mortality, frequency of recurrent cardiovascular events and occurrence ofadverse events, primary disability were determined.Results and discussion. Outcomes of follow-up monitoring against the background of subsidized drug coverage: total one-yearmortality – 1.5% (28 patients, 65.9±6.3 years, men 72.7%). Recurrent cardiovascular events in 12 months – 249 (13.8%) patients (68.4±7.4years, men 182 (73.1%)). 10 patients had significant atrial fibrillation paroxysms requiring hospitalization (0.6%, 59.4±5.8 years, 40.0%men). Recurrent cardiovascular events were significantly more common in men (χ2 7.45; p=0.045). Target LDL-C level of less than 1.4mmol/L were achieved in 270 (15.0%) patients with very high cardiovascular risk. Adverse events were identified: non-fatal bleeding –14 patients (0.8%, 73.4±7.6 years, men 57.1%), transaminitis – 14 patients (0.8%, 70.4±2.3 years, men 71.4%), myalgia on statin therapy –21 patients (1.2%, 71.2±2.5 years, men 52.4%), dyspnea on ticagrelor – 21 patients (1.2%, 58.4±4.3 years, men 47.6%) 1432 patients(95.3%) had no specified adverse events. There was a significant increase in new cases of type 2 DM from 331 (18.3%) to 339 (22.6%; χ2McNemar A/D 4.07; p=0.044; B/C 93.09; p=0.002). High-normal blood glucose levels were observed at baseline in 384 patients (21.3%);by the end of follow-up, the number of patients with high-normal glucose was 540 (30.0%; χ2 86.08; p=0.002). There was a significantdecrease in the number of patients with CHF (from 72 (4.0%) to 45 (3.0%); χ2 McNemar A/D 48.52; p=0.000; B/C 45.14; p=0.034).Conclusion. The results obtained testify to the effectiveness of the ongoing comprehensive program of medical rehabilitation(medication, physical rehabilitation and psychological counseling).


KEYWORDS: preferential drug provision, follow-up monitoring, cardiac rehabilitation

FOR CITATION: Korennova O.Yu., Druk I.V., Podolnaya S.P., Savchenko M.V., Yuhina Yu.E., Ryapolova E.A. Efficacy of Follow-up Monitoring for Patients with Very High Cardiovascular Risk in the Omsk Region. Bulletin of Rehabilitation Medicine. 2022; 21 (3): 121-128. https://doi.org/10.38025/2078-1962-2022-21-3-121-128


References:

  1. Zhuravleva M.V., Zyryanov S.K., Paleev F.N., Yakovlev A.N., Marin T.V., Gagarina Yu.V. Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022- 2024. Russian Journal of Cardiology. 2021; 26(12): 4819 p. https://doi.org/10.15829/1560-4071-2021-4819 (In Russ.).
  2. Shishov M.A. Relevant issues of pharmaceutical benefits. State Power and Local Self-government. 2019: (5): 51-54. https://doi.org/10.18572/1813-1247-2019-5-51-54 (In Russ.).
  3. Podolnaya S.P., Korennova O.Yu., Shukil L.V., Ryapolova E.A., Druk I.V. Ways to improve secondary cardiovascular prevention in patients with acute coronary syndrome. Lechaschi Vrach. 2020: (7): 21-27. https://doi.org/10.26295/OS.2020.65.55.019 (In Russ.).
  4. Shmonin A.A.Problems of adherence to drug therapy in medical rehabilitation. Medical Rehabilitation. 2017: 11(140): 20-27 (In Russ.).
  5. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018;(6):7-122. https://doi.org/10.15829/1560-4071-2018-6-7-122 (In Russ.).
  6. Ivanova G.E., Truhanov A.I. global prospects for the development of medical rehabilitation. Bulletin of Rehabilitation Medicine. 2017; 6(82): 2-6 (In Russ.).
  7. Erlikh A.D. twelve months outcomes in patients with acute coronary syndrome, by the national registry record-3. Russian Journal of Cardiology. 2018; (3): 23-30. https://doi.org/10.15829/1560-4071-2018-3-23-30 (In Russ.).
  8. Ruda M.Y., Averkov O.V., Khomitskaya Y.V. Long-term follow-up of antithrombotic management patterns in patients with acute coronary syndrome in Russia: an observational study (EPICOR-RUS study). Current Medical Research and Opinion. 2017; 33(7): 1269-1276. https://doi.org/10.1080/03007995.2017.1313214 (In Russ.).
  9. Wallentin L., Becker R.C., Budaj A. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New English Journal of Medicine. 2009; 361(11): 1045-57. https://doi.org/10.1056/NEJMoa0904327
  10. Hadi N., Gul E., Muneeb P.M., Khan A., Alam S., Sumaira, Kamal A. Prevalence of depression and anxiety in patients presenting with acute coronary syndrome to mardan medical complex. Pakistan Heart Journal. 2021; 53(4): 359-365. https://doi.org/10.47144/PHJ.V53I4.1971
  11. Tsuda K., Kataoka Y., Ogata S. Diminished response to statins predicts the occurrence of heart failure after acute myocardial infarction. Cardiovascular Diagnosis and Therapy. 2020; 10(4): 705-716. https://doi.org/10.21037/cdt-20-415
  12. Bradley S.M., Hess G.P., Stewart P. et al. Implications of the PEGASUS-TIMI 54 trial for US clinical practice. OpenHeart. 2017; 4(1): 580. https://doi.org/10.1136/openhrt-2016-000580
  13. Sionis A., Catapano A.L., De Ferrari G.M., Dudek D., Jukema J.W., Landmesser U., Pirillo A., Schiele F., Zaman A., Zamorano J.L. Improving lipid management in patients with acute coronary syndrome: the ACS lipid EuroPath tool. Atherosclerosis Supplements. 2020; 42(1): 65-71. https://doi.org/10.1016/j.atherosclerosissup.2021.01.011.



Creative Commons License
The content is available under the Creative Commons Attribution 4.0 License.

©


This is an open article under the CC BY 4.0 license. Published by the National Medical Research Center for Rehabilitation and Balneology.